Trial Profile
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Mar 2021
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary)
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Hodgkin's disease; Mantle-cell lymphoma; Myelodysplastic syndromes; Myelofibrosis; Myeloproliferative disorders; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Infinity Pharmaceuticals; Verastem Oncology
- 07 Mar 2019 Results (n=31) assessing clinical activity in indolent non-hodgkin's lymphoma patients, published in the Verastem Oncology Media Release.
- 07 Mar 2019 According to a Verastem Oncology Media Release, data from this study and NCT01882803, NCT02004522,NCT02049515 was presented at the 23rd Annual International Congress on Hematologic Malignancies (ICHM), which took place February 28 to March 3, 2019, in Miami, Florida.
- 04 Dec 2018 Results of pooled analysis evaluating efficacy and safety analysis from [NCT01476657],[NCT01882803],[NCT02004522],[NCT02049515) studies in RR CLL/SLL, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.